A randomized, double-blind, placebo-controlled, parallel-group clinical trial to examine the efficacy and safety of early pramipexole treatment versus delayed pramipexole treatment in patients with new onset Parkinson's disease

Trial Profile

A randomized, double-blind, placebo-controlled, parallel-group clinical trial to examine the efficacy and safety of early pramipexole treatment versus delayed pramipexole treatment in patients with new onset Parkinson's disease

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Aug 2014

At a glance

  • Drugs Pramipexole (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Acronyms PROUD
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 01 Aug 2013 Primary endpoint 'Unified-Parkinson's-Disease-Rating-Scale' has not been met.
    • 11 Jun 2010 Study details were published in Movement Disorders.
    • 12 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top